Literature DB >> 10542944

Prognostic factors in Paget's disease of the vulva: a study of 21 cases.

D Crawford1, M Nimmo, P B Clement, T Thomson, J L Benedet, D Miller, C B Gilks.   

Abstract

Twenty-one cases of vulvar Paget's disease were studied to assess possible prognostic indicators, including presence and depth of invasion, status of resection margins, tumor DNA cell content, and immunoreactivity for p53 and estrogen receptor proteins. Immunostaining for cytokeratin 7 (CK7), cytokeratin 20 (CK20), and gross cystic disease fluid protein-15 (GCDFP) were also performed. Patients were 45 to 82 years of age (mean, 66.9 years). Ten of 21 patients (47.6%) had invasive Paget's disease. Dermal invasion was < or = 1 mm in 7 of 10 cases and 2 mm, 3 mm, and 8 mm in the remaining three invasive tumors. Of the seven patients with minimally invasive Paget's disease (< or = 1 mm depth of invasion), five are alive with no evidence of disease, one died of an unrelated illness, and one is alive with biopsy-proven in situ Paget's disease, having refused operative treatment. Of the three patients with more than minimally invasive Paget's disease (> 1 mm), all had nodal metastases; one patient is alive with no evidence of disease, one died of undertermined causes, and one died of metastatic Paget's disease. The remaining 11 patients had Paget's disease confined to the epidermis and its adnexal structures. Seven of these patients were alive at last follow-up with no evidence of disease. Of the remaining four patients, one died of metastatic cervical cancer, one died of metastatic bladder cancer, one died of an unrelated illness, and one patient is alive with biopsy-proven in situ Paget's disease and awaiting operative treatment. Twenty of the 21 cases represented primary vulvar Paget's disease while one represented possible local spread from a cervical adenocarcinoma. The immunoprofiles were GCDFP+/CK7+/CK20- in 14 cases, GCDFP+/CK7+/CK20+ in 4 cases, and GCDFP-/CK7+/CK20- in 2 cases. All tumors were estrogen receptor-negative. Immunostaining for p53 was positive in 16 tumors and negative in four tumors. Seven of 12 (58%) patients with positive margins experienced local recurrence of Paget's disease, while the disease recurred in 1 of 4 patients with negative margins. Recurrence was observed in 3 of 5 patients with diploid tumors and in 4 of 10 patients with aneuploid tumors. Neither of these differences is statistically significant. This study supports the recognition of a category of minimally invasive vulvar Paget's disease that has a low risk of distant metastasis and death caused by disease. Status of surgical resection margins, tumor cell DNA ploidy, estrogen receptor expression, and p53 immunoreactivity are not predictive of local recurrence.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10542944     DOI: 10.1097/00004347-199910000-00010

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  10 in total

Review 1.  Mammary and extramammary Paget's disease.

Authors:  J Lloyd; A M Flanagan
Journal:  J Clin Pathol       Date:  2000-10       Impact factor: 3.411

2.  Paget's disease of the vulva: a clinicopathologic institutional review.

Authors:  Alberto A Mendivil; Lisa Abaid; Howard D Epstein; Mark A Rettenmaier; John V Brown; John P Micha; Marie A Wabe; Bram H Goldstein
Journal:  Int J Clin Oncol       Date:  2011-10-01       Impact factor: 3.402

Review 3.  [TNM classification of gynecologic malignancies : What remains to be done beyond 2017?]

Authors:  L-C Horn; C E Brambs; S Opitz; J Einenkel; D Mayr
Journal:  Pathologe       Date:  2019-02       Impact factor: 1.011

4.  Genomic Alterations as Potential Therapeutic Targets in Extramammary Paget's Disease of the Vulva.

Authors:  Marina Stasenko; Gowtham Jayakumaran; Renee Cowan; Vance Broach; Dennis S Chi; Anthony Rossi; Travis J Hollman; Ahmet Zehir; Nadeem R Abu-Rustum; Mario M Leitao
Journal:  JCO Precis Oncol       Date:  2020-09-15

5.  Paget's Disease of the Vulva in Premenopausal Woman Treated with Only Surgery: A Case Report.

Authors:  Hamid Asmouki; Rachid Oumouloud; Abderrahim Aboulfalah; Abderraouf Soummani; Abdelouahed Marrat
Journal:  Case Rep Oncol Med       Date:  2012-09-16

6.  Interventions for the treatment of Paget's disease of the vulva.

Authors:  Katharine A Edey; Ernest Allan; John B Murdoch; Susan Cooper; Andrew Bryant
Journal:  Cochrane Database Syst Rev       Date:  2019-06-05

7.  Tumor Wide Horizontal Invasion Predicts Local Recurrence for Scrotal Extramammary Paget's Disease.

Authors:  Lujia Wang; Chenchen Feng; Minwei Zhou; Zhongwen Zhou; Guanxiong Ding; Peng Gao; Qiang Ding; Zhong Wu
Journal:  Sci Rep       Date:  2017-03-21       Impact factor: 4.379

8.  Extramammary Paget disease of the vulva: immunohistochemical analysis of neoangiogenesis and epithelial-mesenchymal transition markers expression.

Authors:  Lara Alessandrini; Nicolò Clemente; Tiziana Perin; Giorgio Giorda; Vincenzo Canzonieri; Francesco Sopracordevole
Journal:  Diagn Pathol       Date:  2018-01-03       Impact factor: 2.644

9.  Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease.

Authors:  Zoran Gatalica; Semir Vranic; Božo Krušlin; Kelsey Poorman; Phillip Stafford; Denisa Kacerovska; Wijendra Senarathne; Elena Florento; Elma Contreras; Alexandra Leary; April Choi; Gino K In
Journal:  Cancer Med       Date:  2020-01-03       Impact factor: 4.452

10.  Chemokine Receptors CXCR4 and CXCR7 are Associated with Tumor Aggressiveness and Prognosis in Extramammary Paget Disease.

Authors:  Kun Chang; Gao-Xiang Li; Yun-Yi Kong; Xu-Xia Shen; Yuan-Yuan Qu; Zhong-Wei Jia; Yue Wang; Bo Dai; Ding-Wei Ye
Journal:  J Cancer       Date:  2017-08-02       Impact factor: 4.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.